<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01036932</url>
  </required_header>
  <id_info>
    <org_study_id>IEC MAMC 179</org_study_id>
    <nct_id>NCT01036932</nct_id>
  </id_info>
  <brief_title>Granulocyte Colony Stimulating Factor(G-CSF) Therapy for Patients With ACLF</brief_title>
  <official_title>To Study the Safety and Efficacy of G-CSF Therapy on the CD 34 Cell Mobilization and Outcome of Patients With ACLF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Govind Ballabh Pant Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Govind Ballabh Pant Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether Granulocyte Colony Stimulating factor(G-CSF)
      therapy is effective in the treatment of patients with Acute on chronic liver failure(ACLF).
      The investigators hypothesize that ACLF is a disease where severe hepatic impairment is
      accompanied by impaired hepatic regeneration. BMC mobilization using G-CSF therapy, or G-CSF
      therapy per se would increase the regenerative capacity of the liver and shall lead to
      clinical, biochemical and histological improvements in patients with ACLF.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mobilization of CD34 cells in the peripheral blood</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical/ biochemical improvement in liver function profile</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of multi-organ failure</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute on Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>G-CSF group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with Acute on chronic liver failure after baseline investigations for the etiology of the acute event and the underlying chronic disease were given Granulocyte Colony Stimulating Factor therapy for a total duration of one month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After baseline characterization and work up for underlying acute and chronic liver disease, patients were given placebo along with the standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte Colony Stimulating Factor</intervention_name>
    <description>Dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.</description>
    <arm_group_label>G-CSF group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>dose of 1ml s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with acute hepatic insult manifesting as jaundice (Sr. Bil. ≥5 mg/dL) and
             coagulopathy (INR≥1.5), complicated within 4 weeks by ascites and/or encephalopathy in
             a patient with previously diagnosed or undiagnosed chronic liver disease.(APASL
             criteria)

        Exclusion Criteria:

          -  HCC or portal vein thrombosis. Refusal to participate in the study. Sepsis ( Any
             culture positive: blood, urine, focus of infection on Xray chest, any other obvious
             source of infection: UTI, SBP) Multi organ failure. Grade 3 or 4 hepatic
             encephalopathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiv K Sarin, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>G B Pant Hospital, New Delhi, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shiv K Sarin</name>
      <address>
        <city>New Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiv K Sarin, MD, DM</last_name>
      <phone>91-11-23234242</phone>
      <phone_ext>5201</phone_ext>
      <email>shivsarin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Shiv K Sarin, MD, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>December 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <last_update_submitted>December 18, 2009</last_update_submitted>
  <last_update_submitted_qc>December 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr S.K.Sarin</name_title>
    <organization>Head, Gastroenterology</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

